Hormone Therapy and Chemotherapy

Differential Treatment Response for Hormone Sensitive Men with Nodal Metastases – Nodal Burden as a Prognostic Biomarker

Differential Treatment Response for Hormone Sensitive Men with Nodal Metastases – Nodal Burden as a Prognostic Biomarker

Men with prostate cancer with both nodal and bone metastases due worse with ADT plus docetaxel chemotherapy than men with only bone metastases. In addition, increased nodal metastases burden is a negative prognostic biomarker.